Clinical evaluation of bioactive glass in the treatment of periodontal intrabony defects.
To evaluate the effect of a new product of bioactive glass, Perioglas((R)) on human periodontal intrabony defects. Twenty periodontal intrabony defects in 10 healthy adults were selected. Four weeks after an initial therapy, they were randomly assigned to either a BAG experimental (open flap debridement with BAG, totally 13 defects) or a control OFD (simple open flap debridement, totally 7 defects) group. For both groups, routine flap procedure was performed, but the Perioglas((R)) was implanted only in the BAG group. The followings were recorded before the operation and repeated at the 3rd and 6th month evaluations: plaque index (PLI), bleeding index (BI), gingival recession (REC), probing depth (PD) and clinical attachment loss (CAL). At the 3rd and 6th months after operation, both groups showed significant reduction in PD and CAL. PD and CAL in BAG group at baseline were 6.19 mm and 6.31 mm, which were 3.23 mm and 3.65 mm at 6th after surgery, respectively. PD and CAL in OFD group at baseline were 6.86 mm and 7.71 mm, which were 4.50 mm and 5.35 mm at 6 th after surgery, respectively. And the BAG group showed significant reduction in BI, which from 2.77 at baseline to 0.65 at 6th month post-operation. BI, PD and CAL in BAG group were significantly lower than those in OFD group. The reduction of BI in BAG group was significantly more than that in OFD group. The bioactive glass is effective as an adjunct to conventional surgery in the treatment of intrabony defects.